U.S. market Closed. Opens in 1 day 16 hours 17 minutes

VKTX | Viking Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue292.00K291.00K296.00K277.00K260.00KN/AN/AN/AN/AN/AN/A
Gross Profit-292.00K-291.00K-296.00K-277.00K-260.00KN/AN/AN/AN/AN/AN/A
Operating Expenses100.83M70.36M55.68M42.66M32.69M26.16M19.07M13.85M12.00MN/AN/A
Selling, General & Admin37.02M16.12M10.70M10.73M9.13M7.12M5.33M4.85M5.03M1.24M89.46K
Research & Development63.81M54.23M44.98M31.93M23.56M19.04M13.74M9.00M6.97M22.22M11.61K
Other Operating ExpensesN/AN/AN/AN/AN/A1.40MN/AN/AN/AN/AN/A
Operating Income-100.83M-70.36M-55.68M-42.66M-32.69M-26.16M-19.07M-13.85M-12.00M-23.47M-101.08K
Other Expenses / Income14.93M1.49M692.00K3.17M6.91M1.39M-1.51M-884.55K-11.41M1.58M-45.17K
Before Tax Income-85.89M-68.87M-54.99M-39.49M-25.78M-22.06M-20.58M-14.73M-23.40M-21.88M-146.25K
Income Tax Expenses-292.00K-1.49M-988.00K-3.44M6.99M-2.71MN/AN/AN/AN/AN/A
Net Income-85.89M-67.38M-54.00M-36.05M-25.78M-22.06M-20.58M-14.73M-23.40M-21.88M-146.25K
Interest Expenses88.00K-1.49M18.00K106.00K146.00K404.00K1.28M1.81M982.18K628.68K24.55K
Basic Shares Outstanding94.35M76.83M77.20M72.60M71.96M57.58M25.98M16.28M6.36M4.31M4.31M
Diluted Shares Outstanding94.35M76.83M77.20M72.60M71.96M57.58M25.98M16.28M6.36M4.31M4.31M
EBITDA-100.83M-70.31M-55.69M-42.70M-25.52M-21.65M-19.30M-12.92M-22.42M-21.26M-121.70K
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-86.10M-70.36M-54.97M-39.39M-18.64M-24.37M-19.30M-12.92M-22.42M-21.26M-121.70K
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙